Tag Archives: Stelara®

Fresenius Kabi and Formycon Receive European Approval for Ustekinumab Biosimilar FYB202

Posted on 27, September 2024 by

(IN BRIEF) Fresenius Kabi, in collaboration with Formycon, has received approval from the European Commission (EC) for FYB202, a biosimilar of ustekinumab (marketed as Stelara® by Johnson & Johnson). This biosimilar is approved for the treatment of serious inflammatory diseases. … Read the full press release →

Posted in Business, Environment, Financial, Germany, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Security & Safety, Technology

Tagged , , , , , , ,